Tight Glycemic Control in Acute Exacerbations of COPD

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00452296

Enrollment

Registered

2007-03-27

Start date

2007-04-30

Completion date

2012-12-31

Last updated

2012-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Hyperglycemia

Keywords

inpatients with COPD, glucose control

Brief summary

Glucose control has been shown as an important and independent prognostic factor in several acute conditions in hospitalized patients, including Acute MI, stroke, cardiac surgery and in critical care units. Patients with acute exacerbation of COPD (AECOPD)and diabetes treated with insulin had a longer in-patient stay and more frequent isolation of Gram negative bacteria from sputum than those without diabetes.Hyperglycemia (\>11 mmol/l) on admission predicted failure of non-invasive ventilation and infectious pulmonary complications in patients admitted to the ICU with acute respiratory failure caused by severe AECOPD. The primary goal of this study is to test the hypothesis that in AECOPD, tight glycemic control during hospital stay will improve outcome of hospitalization. The secondary goal of this study is to test new ways in controlling patients in the internal medicine ward.

Interventions

DRUGtight insulin treatment in patients hospitalized with COPD exacerbation

treatment with basal plus bolus insulin

PROCEDUREtight glycemic control

treatment with basal and bolus insulin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 90 Years

Healthy volunteers

Inclusion criteria

* current or past smokers (at least 20 py) * patient with COPD be ATS criteria * hospitalized with acute exacerbation, 2/3 criteria:1- worsening of SOB 2-change in sputum volume 3- change in sputum color * signed informed concent

Exclusion criteria

* respiratory failure (pH\<7.35 ו Pco2\>60 ) * pneumonia * pneumothorax * bronchiectasis * lung collapse * congestive heart failure * lung cancer * suspected pulmonary emboli * immune deficiency (acquired 0r congenital) * cystic fibrosis * post lung implantation * asthma/ non smokers

Design outcomes

Primary

Measure	Time frame
mortality	one year

Secondary

Measure	Time frame
hospialization	one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026